These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 34743329)

  • 1. Tumor-immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas.
    Soeratram TT; Creemers A; Meijer SL; de Boer OJ; Vos W; Hooijer GK; van Berge Henegouwen MI; Hulshof MC; Bergman JJ; Lei M; Bijlsma MF; Ylstra B; van Grieken NC; van Laarhoven HW
    J Pathol; 2022 Mar; 256(3):282-296. PubMed ID: 34743329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High CD8
    Koemans WJ; van Dieren JM; van den Berg JG; Meijer GA; Snaebjornsson P; Chalabi M; Lecot F; Riedl R; Krijgsman O; Hofland I; Broeks A; Voncken FEM; Peppelenbosch MP; Sosef MN; van Sandick JW; Kodach LL
    Histopathology; 2021 Aug; 79(2):238-251. PubMed ID: 33660299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Dynamic and Transient Immune Microenvironment in Locally Advanced Esophageal Adenocarcinoma Post Chemoradiation.
    Kelly RJ; Zaidi AH; Smith MA; Omstead AN; Kosovec JE; Matsui D; Martin SA; DiCarlo C; Werts ED; Silverman JF; Wang DH; Jobe BA
    Ann Surg; 2018 Dec; 268(6):992-999. PubMed ID: 28806299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation.
    Humphries MP; Craig SG; Kacprzyk R; Fisher NC; Bingham V; McQuaid S; Murray GI; McManus D; Turkington RC; James J; Salto-Tellez M
    BMC Cancer; 2020 Jun; 20(1):500. PubMed ID: 32487090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer.
    Teng F; Meng X; Kong L; Mu D; Zhu H; Liu S; Zhang J; Yu J
    Transl Res; 2015 Dec; 166(6):721-732.e1. PubMed ID: 26209749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoradiation-induced alteration of programmed death-ligand 1, CD8+ tumor-infiltrating lymphocytes and mucin expression in rectal cancer.
    Baretti M; Zhu Q; Fu W; Meyer J; Wang H; Anders RA; Azad NS
    Oncotarget; 2022; 13():907-917. PubMed ID: 35937503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P53 and SOX2 Protein Expression Predicts Esophageal Adenocarcinoma in Response to Neoadjuvant Chemoradiotherapy.
    van Olphen SH; Biermann K; Shapiro J; Wijnhoven BP; Toxopeus EL; van der Gaast A; Stoop HA; van Lanschot JJ; Spaander MC; Bruno MJ; Looijenga LH
    Ann Surg; 2017 Feb; 265(2):347-355. PubMed ID: 28059963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association between the tumor immune microenvironments and clinical outcome in low-grade, early-stage endometrial cancer patients.
    López-Janeiro Á; Villalba-Esparza M; Brizzi ME; Jiménez-Sánchez D; Ruz-Caracuel I; Kadioglu E; Masetto I; Goubert V; Garcia-Ros D; Melero I; Peláez-García A; Hardisson D; de Andrea CE
    J Pathol; 2022 Dec; 258(4):426-436. PubMed ID: 36169332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of IgG4+ plasma cell infiltrates following neoadjuvant chemoradiation therapy for esophageal adenocarcinoma.
    Yakirevich E; Lu S; Allen D; Mangray S; Fanion JR; Lombardo KA; Safran H; Resnick MB
    Hum Pathol; 2017 Aug; 66():126-135. PubMed ID: 28666927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumoral budding and automated CD8-positive T-cell density in pretreatment biopsies can predict response to neoadjuvant therapy in rectal adenocarcinoma.
    Farchoukh L; Hartman DJ; Ma C; Celebrezze J; Medich D; Bahary N; Frank M; Pantanowitz L; Pai RK
    Mod Pathol; 2021 Jan; 34(1):171-183. PubMed ID: 32661298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of PD-L1 expression with CD8+ T cells and oxidative stress-related molecules NRF2 and NQO1 in esophageal squamous cell carcinoma.
    Zhang X; Yang Y; Zhao H; Tian Z; Cao Q; Li Y; Gu Y; Song Q; Hu X; Jin M; Jiang X
    J Pathol Clin Res; 2024 Jul; 10(4):e12390. PubMed ID: 38992928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 Expression in Endocervical Adenocarcinoma: Correlation With Patterns of Tumor Invasion, CD8+ Tumor-infiltrating Lymphocytes, and Clinical Outcomes.
    Rivera-Colon G; Chen H; Molberg K; Niu S; Strickland AL; Castrillon DH; Carrick K; Gwin K; Lea J; Zheng W; Lucas E
    Am J Surg Pathol; 2021 Jun; 45(6):742-752. PubMed ID: 33298732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of neoadjuvant chemoradiotherapy on perioperative immune function of patients with locally advanced esophageal cancer.
    Tan JT; Yang Y; Mao NQ; Liu DS; Huang DM; Pan H; Xie T; Pan Q; Yang L; Zhong JH; Zuo CT
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27766708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic tumor constitution is superior to tumor regression grading for evaluating response to neoadjuvant therapy of esophageal adenocarcinoma patients.
    Buck A; Prade VM; Kunzke T; Feuchtinger A; Kröll D; Feith M; Dislich B; Balluff B; Langer R; Walch A
    J Pathol; 2022 Feb; 256(2):202-213. PubMed ID: 34719782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD8+/FOXP3+ ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer.
    Zhu Y; Li M; Mu D; Kong L; Zhang J; Zhao F; Li Z; Liu X; Bo C; Yu J
    Oncotarget; 2016 Nov; 7(44):71455-71465. PubMed ID: 27683115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential Predictive Immune and Metabolic Biomarkers of Tumor Microenvironment Regarding Pathological and Clinical Response in Esophageal Cancer After Neoadjuvant Chemoradiotherapy: A Systematic Review.
    Wang HH; Steffens EN; Kats-Ugurlu G; van Etten B; Burgerhof JGM; Hospers GAP; Plukker JTM
    Ann Surg Oncol; 2024 Jan; 31(1):433-451. PubMed ID: 37777688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No Survival Difference with Neoadjuvant Chemoradiotherapy Compared with Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: Results from the National Cancer Data Base.
    Al-Sukhni E; Gabriel E; Attwood K; Kukar M; Nurkin SJ; Hochwald SN
    J Am Coll Surg; 2016 Dec; 223(6):784-792.e1. PubMed ID: 27641320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in Indoleamine 2,3-Dioxygenase 1 Expression and CD8+ Tumor-Infiltrating Lymphocytes after Neoadjuvant Chemoradiation Therapy and Prognostic Significance in Esophageal Squamous Cell Carcinoma.
    Zhou S; Yang H; Zhang J; Wang J; Liang Z; Liu S; Li Y; Pan Y; Zhao L; Xi M
    Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):286-294. PubMed ID: 32004580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A study of the immune infiltrate and patient outcomes in esophageal cancer.
    Conroy MJ; Kennedy SA; Doyle SL; Hayes B; Kavanagh M; van der Stok EP; O'Sullivan K; Cathcart MC; Reynolds JV; Lysaght J
    Carcinogenesis; 2021 Apr; 42(3):395-404. PubMed ID: 32940666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.
    Chen TW; Huang KC; Chiang SF; Chen WT; Ke TW; Chao KSC
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):1043-1053. PubMed ID: 30874889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.